ENGNW
enGene Holdings Inc. Warrants
$0.27
+0.01
(+6.00%)
Mkt Cap
13.57M
Volume
39,300
52W Range
0.25-2.1
Sector
Healthcare
Beta
-0.29
EPS (TTM)
-1.24
P/E Ratio
-3.14
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (117.30M) | (55.14M) | (99.92M) | (24.46M) | (23.44M) | (15.07M) |
| EPS | -2.29 | -1.46 | -4.24 | 0.00 | -0.01 | -0.95 |
| Free Cash Flow | (100.72M) | (49.21M) | (25.06M) | (17.75M) | (16.23M) | (13.25M) |
| FCF / Share | -1.97 | -1.10 | -1.06 | -1.12 | -1.03 | -0.84 |
| Operating CF | (99.24M) | (48.28M) | (24.74M) | (17.59M) | (15.98M) | (13.06M) |
| Total Assets | 221.47M | 311.17M | 86.96M | 132.04M | 131.45M | N/A |
| Total Debt | 31.80M | 25.02M | 9.78M | 0 | 0 | N/A |
| Cash & Equiv | 50.15M | 173.00M | 81.52M | 314,151 | 1.07M | N/A |
| Book Value | 167.71M | 272.61M | 72.49M | 127.42M | 127.39M | N/A |
| Return on Equity | -0.70 | -0.20 | -1.38 | -0.19 | -0.18 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (29.75M) | (37.88M) | (28.99M) | (25.82M) | (24.62M) | (15.30M) | (14.15M) | (14.98M) | (10.71M) | (82.50M) | (4.72M) | (5.28M) |
| EPS | -0.44 | -0.74 | -0.57 | 0.51 | -0.48 | -0.34 | -0.32 | -0.38 | -0.46 | -2.64 | -0.26 | -0.28 |
| Free Cash Flow | (29.06M) | (25.40M) | (26.34M) | (22.99M) | (26.00M) | (19.81M) | (7.18M) | (14.34M) | (7.88M) | (6.91M) | (7.46M) | (4.45M) |
| FCF / Share | -0.43 | -0.50 | -0.52 | -0.45 | -0.51 | -0.44 | -0.16 | -0.36 | -0.34 | -0.22 | -0.47 | -0.28 |
| Operating CF | (28.90M) | (24.96M) | (25.63M) | (22.95M) | (25.70M) | (19.57M) | (7.18M) | (14.16M) | (7.37M) | (6.78M) | (7.30M) | (4.44M) |
| Total Assets | 337.11M | 221.47M | 245.55M | 266.65M | 285.93M | 311.17M | 266.88M | 273.53M | 93.42M | 86.96M | 136.10M | 133.56M |
| Total Debt | 33.46M | 31.80M | 31.38M | 25.36M | 25.13M | 25.02M | 24.86M | 24.68M | 24.52M | 9.78M | 2.46M | 450,000 |
| Cash & Equiv | 36.61M | 50.15M | 32.62M | 57.55M | 62.35M | 173.00M | 257.68M | 264.81M | 85.65M | 81.52M | 269,138 | 474,437 |
| Book Value | 281.55M | 167.71M | 200.67M | 227.29M | 249.95M | 272.61M | 230.33M | 242.97M | 62.38M | 72.49M | 124.36M | 127.07M |
| Return on Equity | -0.11 | -0.23 | -0.14 | -0.11 | -0.10 | -0.06 | -0.06 | -0.06 | -0.17 | -1.14 | -0.04 | -0.04 |
ENGNW News
No news available for ENGNW.